リツキシマブで治療し，リウマトイド因子が再燃予知因子として有用と考えられた関節リウマチの一例

今田 千晴; 石井 宏治; 高野 久仁子; 大村 雄一; 尾崎 貴士; 濱崎 一; 前島 圭佑; 原中 美環; 緒方 正男; 柴田 洋孝

doi:10.14961/cra.28.227

original article

A case of rheumatoid arthritis treated with rituximab; rheumatoid factor was considered to be a useful relapse predictor

Chiharu Imada, Koji Ishii, Kuniko Takano, Yuichi Omura, Takashi Ozaki, Hajime Hamasaki, Keisuke Maeshima, Miwa Haranaka, Masao Ogata, Hirotaka Shibata

Author information

Chiharu Imada
Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University
Koji Ishii
Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University
Kuniko Takano
Department of Medical Oncology and Hematology, Faculty of Medicine, Oita University
Yuichi Omura
Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University
Takashi Ozaki
Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University
Hajime Hamasaki
Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University
Keisuke Maeshima
Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University
Miwa Haranaka
Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University
Masao Ogata
Department of Medical Oncology and Hematology, Faculty of Medicine, Oita University
Hirotaka Shibata
Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University

Keywords: rituximab, rheumatoid arthritis, malignant lymphoma, rheumatoid factor

JOURNAL FREE ACCESS

2016 Volume 28 Issue 3 Pages 227-231

DOI https://doi.org/10.14961/cra.28.227

Details

Abstract

A 68-year-old female was diagnosed with malignant lymphoma while undergoing treatment for rheumatoid arthritis (RA). She was started on chemotherapy including rituximab (RTX). Consequently, malignant lymphoma remitted, and RA improved. However, when RA recurred approximately 1 year after the chemotherapy, RTX treatment was repeated following which the symptoms disappeared, and this effect was maintained for about 1 year. RA recurred at an interval of approximately 1 year, and it improved each time with RTX treatment. Increase in rheumatoid factor was detected just before RA recurrences. Therefore, rheumatoid factor was considered to be a useful predictor of RA recurrence.

Corresponding author

Register with J-STAGE for free!